Thrombocytopenia
Thrombocytopenia Content
Journal articles and more to your inbox
Get the latest clinical insights from touchHAEMATOLOGY
Sign me up!
Feedback
We’d love to hear your feedback on this activity. It helps us to continually improve our products.
CORRECT!
Faculty & Disclosures
Prof. Cindy Neunert
Columbia University Irving Medical Center, New York, NY, USA
Prof. Cindy Neunert is an associate professor of paediatrics at Columbia University in New York. read more
She received fellowship training in paediatric haematology–oncology at the University of Texas Southwestern Medical School at Dallas in Texas, where she also obtained her master’s degree in clinical research.
Her research interests involve assessing patient-related outcomes in disorders of haemostasis and thrombosis. She was chair of the 2019 American Society of Hematology guidelines on the diagnosis and management of immune thrombocytopenia (ITP). She works closely with the Intercontinental Cooperative ITP Study Group and is the former chair of the Pediatric ITP Consortium of North America.
Prof. Cindy Neunert discloses: Advisory board or panel fees from Janssen; Argenx, Sanofi and Sobi (relationships terminated). Other financial or material support from Genzyme and Sanofi (relationships terminated).
Prof. David Kuter
Massachusetts General Hospital, Boston, MA, USA
Prof. David Kuter is chief of haematology at Massachusetts General Hospital (MGH) and professor of medicine at Harvard Medical School in Boston. read more
Prof. Kuter divides his time between medical education of fellows and medical students, clinical care of patients with a wide range of haematological disorders, basic science investigation into thrombopoietin and megakaryocyte biology, and clinical research related to thrombopoietic agents and haemolytic anaemia. His basic science group was one of the laboratories that discovered thrombopoietin and his clinical research group carried out various seminal studies using thrombopoietic agents in transfusion medicine, chemotherapy-induced thrombocytopenia and immune thrombocytopenia.
A member of the American Society of Hematology (ASH), Prof. Kuter is the recipient of a number of awards, including the Irving M. London Teaching Award at Harvard Medical School; the Alfred Kranes Teaching Award at MGH; the 2008 and 2010 Douglas Family Foundation Prize, recognizing excellence in haematology–oncology research at the MGH Cancer Center; the Jane Green Memorial Prize, recognizing excellence in haematology–oncology teaching at the MGH Cancer Center; the 2013 Ernest Beutler Award from ASH; the Thomas R. Spitzer Outstanding Clinician Award at the MGH Cancer Center; and the 2023 MacFarlane Biggs Plenary Lectureship of the British Society for Haematology/British Society for Haemostasis and Thrombosis.
Prof. Kuter has given over 700 invited lectures in over 50 countries and served as a visiting professor in Beijing, Sydney, Tokyo, London, Durham, Little Rock, Tianjin, Melbourne, and New Haven. Prof. Kuter has authored or co-authored over 350 articles published in international, peer-reviewed journals, including the New England Journal of Medicine, The Lancet and Blood.
Prof. David Kuter discloses: Consultant for Alexion, Alpine, Amgen, Apellis, Argenx, BioCryst, Bristol Myers Squibb, Caremark, Cellphire, Cellularity, Chugai, Hengrui, Hutchmed, Immunovant, Inmagenebio, Ligand, Merck Sharp Dohme, Novartis, Pfizer, Principia, Regeneron, Rigel, Sanofi, Seismic, Sobi, Takeda, UCB and Verve. Grants/research support from Biocrystal, Hutchmed, Novartis, Principia, Rigel and Sanofi.
Dr María Eva Mingot Castellano
Hospital Universitario Virgen del Rocío, Seville, Spain
Dr María Eva Mingot Castellano is the head of transfusion and tissue establishment area in the Hematology Department, including apheresis and cryopreservation, at the Virgen del Rocío University Hospital, in Seville, Spain. read more
From 2005 to 2019 she was responsible for haemostasis and thrombosis in adults in the Hematology Department of the Regional University Hospital of Malaga. She has been an associate professor at the University of Seville since 2023 and at the University of Malaga from 2011 to 2019.
Dr Mingot Castellano is a member of the board of the Spanish Society of Thrombosis and Haemostasis and the Transfusion Accreditation Committee; vice president of the Spanish Apheresis Group; treasurer reference of the Spanish Immune Thrombocytopenia (ITP) Working Group; and coordinator of the Spanish and Portuguese thrombotic thrombocytopenic purpura (TTP) Registry, the Spanish registry of acquired haemophilia, the national ITP and TTP guidelines.
As of January 2024, Dr Mingot Castellano had 185 documents in Web of Science. Her main areas of interest are immune cytopenias (immune haemolytic anaemia, ITP, TTP, congenital immune cytopenia, acquired haemophilia), critical bleeding, clinical transfusion, haemovigilance and patient blood management.
Dr María Eva Mingot Castellano discloses: Advisory board or panel fees from Amgen, Grifols, Novartis, Novo Nordisk, Sanofi, Sobi and Takeda. Consultant for Amgen, Grifols, Novartis, Novo Nordisk, Sanofi, Sobi and Takeda. Grants/research support from Amgen, Grifols, Novartis, Novo Nordisk, Sanofi, Sobi and Takeda. Speaker’s bureau fees from Amgen, Grifols, Novartis, Novo Nordisk, Sanofi, Sobi and Takeda.
